- Home
- LAB vs CKPT Comparison
LAB vs CKPT Comparison
Compare LAB & CKPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAB
- CKPT
- Stock Information
- Founded
- LAB 1999
- CKPT 2014
- Country
- LAB United States
- CKPT United States
- Employees
- LAB N/A
- CKPT N/A
- Industry
- LAB Biotechnology: Laboratory Analytical Instruments
- CKPT Biotechnology: Pharmaceutical Preparations
- Sector
- LAB Industrials
- CKPT Health Care
- Exchange
- LAB Nasdaq
- CKPT Nasdaq
- Market Cap
- LAB 451.0M
- CKPT 361.1M
- IPO Year
- LAB 2011
- CKPT 2017
- Fundamental
- Price
- LAB $0.92
- CKPT $4.19
- Analyst Decision
- LAB Buy
- CKPT Buy
- Analyst Count
- LAB 2
- CKPT 3
- Target Price
- LAB $2.50
- CKPT $4.33
- AVG Volume (30 Days)
- LAB 1.4M
- CKPT 962.2K
- Earning Date
- LAB 05-06-2025
- CKPT 05-13-2025
- Dividend Yield
- LAB N/A
- CKPT N/A
- EPS Growth
- LAB N/A
- CKPT N/A
- EPS
- LAB N/A
- CKPT N/A
- Revenue
- LAB $169,687,000.00
- CKPT $41,000.00
- Revenue This Year
- LAB N/A
- CKPT $102,182.93
- Revenue Next Year
- LAB $12.18
- CKPT $351.71
- P/E Ratio
- LAB N/A
- CKPT N/A
- Revenue Growth
- LAB 33.86
- CKPT N/A
- 52 Week Low
- LAB $0.92
- CKPT $1.75
- 52 Week High
- LAB $2.68
- CKPT $4.50
- Technical
- Relative Strength Index (RSI)
- LAB 35.28
- CKPT 72.12
- Support Level
- LAB $1.00
- CKPT $4.14
- Resistance Level
- LAB $1.09
- CKPT $4.20
- Average True Range (ATR)
- LAB 0.09
- CKPT 0.02
- MACD
- LAB -0.02
- CKPT -0.01
- Stochastic Oscillator
- LAB 0.55
- CKPT 83.33
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.